1. Abu-Rustum N.R., Yashar C.M., Arend R., Barber E., Bradley K., Brooks R., Campos S.M., Chino J., Chon H.S., Crispens M.A., Damast S., Fisher C.M., Frederick P., Gaffney D.K., Gaillard S., Giuntoli R., II, Glaser S., Holmes J., Howitt B.E., Kendra K., Lea J., Lee N., Mantia-Smaldone G., Mariani A., Mutch D., Nagel C., Nekhlyudov L., Podoll M., Rodabaugh K., Salani R., Schorge J., Siedel J., Sisodia R., Soliman P., Ueda S., Urban R., Wethington S.L., Wyse E., Zanotti K., McMillian N.,Espinosa S., Vulvar cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 22(2): 117-135, 2024. PMID38503056.
2. Anderson E.C., DiPalazzo J., Lucas F.L., Hall M.J., Antov A., Helbig P., Bourne J., Graham L., Gaitor L., Lu-Emerson C., Bradford L.S., Inhorn R., Sinclair S.J., Brooks P.L., Thomas C.A., Rasmussen K., Han P.K.J., Liu E.T., Rueter J., Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (mcgi). NPJ Precis Oncol. 8(1): 67, 2024. PMID38461318. PMC10924947.
3. Barham D.W., Pyrgidis N., Amini E., Hammad M., Miller J., Andrianne R., Burnett A.L., Gross K., Hatzichristodoulou G., Hotaling J., Hsieh T.C., Jenkins L.C., Jones J.M., Lentz A., Modgil V., Osmonov D., Park S.H., Pearce I., Perito P., Sadeghi-Nejad H., Sempels M., Suarez-Sarmiento A., Simhan J., van Renterghem K., Warner J.N., Ziegelmann M., Yafi F.A., Gross M.S., Does climate impact inflatable penile prosthesis infection (ipp) risk? Assessment of temperature and dew point on ipp infections. J Sex Med, 2024. PMID38481017.
4. Barnes D.R., Tyrer J.P., Dennis J., Leslie G., Bolla M.K., Lush M., Aeilts A.M., Aittomäki K., Andrieu N., Andrulis I.L., Anton-Culver H., Arason A., Arun B.K., Balmaña J., Bandera E.V., Barkardottir R.B., Berger L.P.V., de Gonzalez A.B., Berthet P., Białkowska K., Bjørge L., Blanco A.M., Blok M.J., Bobolis K.A., Bogdanova N.V., Brenton J.D., Butz H., Buys S.S., Caligo M.A., Campbell I., Castillo C., Claes K.B.M., Colonna S.V., Cook L.S., Daly M.B., Dansonka-Mieszkowska A., de la Hoya M., deFazio A., DePersia A., Ding Y.C., Domchek S.M., Dörk T., Einbeigi Z., Engel C., Evans D.G., Foretova L., Fortner R.T., Fostira F., Foti M.C., Friedman E., Frone M.N., Ganz P.A., Gentry-Maharaj A., Glendon G., Godwin A.K., González-Neira A., Greene M.H., Gronwald J., Guerrieri-Gonzaga A., Hamann U., Hansen T.V.O., Harris H.R., Hauke J., Heitz F., Hogervorst F.B.L., Hooning M.J., Hopper J.L., Huff C.D., Huntsman D.G., Imyanitov E.N., Izatt L., Jakubowska A., James P.A., Janavicius R., John E.M., Kar S., Karlan B.Y., Kennedy C.J., Kiemeney L., Konstantopoulou I., Kupryjanczyk J., Laitman Y., Lavie O., Lawrenson K., Lester J., Lesueur F., Lopez-Pleguezuelos C., Mai P.L., Manoukian S., May T., McNeish I.A., Menon U., Milne R.L., Modugno F., Mongiovi J.M., Montagna M., Moysich K.B., Neuhausen S.L., Nielsen F.C., Noguès C., Oláh E., Olopade O.I., Osorio A., Papi L., Pathak H., Pearce C.L., Pedersen I.S., Peixoto A., Pejovic T., Peng P.C., Peshkin B.N., Peterlongo P., Powell C.B., Prokofyeva D., Pujana M.A., Radice P., Rashid M.U., Rennert G., Richenberg G., Sandler D.P., Sasamoto N., Setiawan V.W., Sharma P., Sieh W., Singer C.F., Snape K., Sokolenko A.P., Soucy P., Southey M.C., Stoppa-Lyonnet D., Sutphen R., Sutter C., Teixeira M.R., Terry K.L., Thomsen L.C.V., Tischkowitz M., Toland A.E., Van Gorp T., Vega A., Velez Edwards D.R., Webb P.M., Weitzel J.N., Wentzensen N., Whittemore A.S., Winham S.J., Wu A.H., Yadav S., Yu Y., Ziogas A., Berchuck A., Couch F.J., Goode E.L., Goodman M.T., Monteiro A.N., Offit K., Ramus S.J., Risch H.A., Schildkraut J.M., Thomassen M., Simard J., Easton D.F., Jones M.R., Chenevix-Trench G., Gayther S.A., Antoniou A.C., Pharoah P.D.P. Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk. medRxiv, 2024. PMID38496424. PMC10942532. [Preprint]
5. Beltrán-Visiedo M., Balachandran S., Galluzzi L., Mre11 mobilizes cgas and drives zbp1-dependent necroptosis. Cell Res, 2024. PMID38443562.
6. Berman E., Shah N.P., Deninger M., Altman J.K., Amaya M., Begna K., Bhatia R., Chan O., Collins R., Curtin P., DeAngelo D.J., Drazer M., Maness L., Metheny L., Mohan S., Moore J., Oehler V., Pratz K., Pusic I., Rose M., Shomali W., Smith B.D., Styler M., Sweet K., Talpaz M., Tanaka T., Tantravahi S., Tsai S., Vaughn J., Welborn J., Yang D., Mauro M., Cortes J., Radich J.,Druker B., CML and the WHO: Why? J Clin Oncol. 42(9): 984-986, 2024. PMID38086008. [Comment]
7. Budyagan K., Cannon A.C., Chatoff A., Snyder N.W., Kurimchak A.M., Duncan J.S., Chernoff J., Kras mutation-selective requirement for acss2 in colorectal adenoma formation. Res Sq, 2024. PMID38464238. PMC10925460. [Pre-print]
8. Cannon A.C., Budagyan K., Uribe-Alvarez C., Kurimchak A.M., Araiza-Olivera D., Cai K.Q., Peri S., Zhou Y., Duncan J.S. Chernoff J., Unique vulnerability of rac1-mutant melanoma to combined inhibition of cdk9 and immune checkpoints. Oncogene. 43(10): 729-743, 2024. PMID38243078.
9. Chen N., McGrath C.B., Ericsson C.I., Vaselkiv J.B., Rencsok E.M., Stopsack K.H., Guard H.E., Autio K.A., Rathkopf D.E., Enting D., Bitting R.L., Mateo J., Githiaka C.W., Chi K.N., Cheng H.H., Davis I.D., Anderson S.G., Badal S.A.M., Bjartell A., Russnes K.M., Heath E.I., Pomerantz M.M., Henegan J.C., Hyslop T., Esteban E., Omlin A., McDermott R., Fay A.P., Popoola A.A., Ragin C., Nowak J., Gerke T., Kantoff P.W., George D.J., Penney K.L.,Mucci L.A., Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the international registry for men with advanced prostate cancer. Cancer Epidemiol Biomarkers Prev. 33(3): 419-425, 2024. PMID38189661. PMC10922505.
10. Chwistek M. Mitigating the risk of aberrant use of opioids in patients with cancer pain. Journal of the National Comprehensive Cancer Network. 21(11): 1212-1213, 2023. PMIDWOS:001171227400013.
11. Deni W.H., Gao T., Wu J., Protocol for reconstituting peptides/peptidomimetics from DMSO to aqueous buffers for circular dichroism analyses. STAR Protoc. 5(1): 102850, 2024. PMID38285735. PMC10839526.
12. Hildebrand E.M., Polovnikov K., Dekker B., Liu Y., Lafontaine D.L., Fox A.N., Li Y., Venev S.V., Mirny L.A., Dekker J., Mitotic chromosomes are self-entangled and disentangle through a topoisomerase-ii-dependent two-stage exit from mitosis. Mol Cell, 2024. PMID38521067.
13. Hutchings H., Behinaein P., Enofe N., Brue K., Tam S., Chang S., Movsas B., Poisson L., Wang A.,Okereke I., Association of social determinants with patient-reported outcomes in patients with cancer. Cancers (Basel). 16(5)2024. PMID38473374. PMC10930456.
14. Iyer S.P., Johnston P.B., Barta S.K., Pralatrexate injection combined with CHOP for treatment of PTCL: Results from the Fol-CHOP dose-finding phase 1 trial. Blood Advances. 8(2): 353-364, 2024. WOS:001166650400001.
15. Johnson C.K., Leung M.M., Ma G.X., Ogunwobi O.O., Effective recruitment strategies utilized to examine dietary practices of Blacks in New York City in the midst of the covid-19 pandemic. J Racial Ethn Health Disparities. 11(2): 764-772, 2024. PMID36929490.PMC10019415.
16. Juric D., Barve M., Vaishampayan U., Roda D., Calvo A., Jañez N.M., Trigo J., Greystoke A., Harvey R.D., Olszanski A.J., Opyrchal M., Spira A., Thistlethwaite F., Jiménez B., Sappal J.H., Kannan K., Riley J., Li C., Li C., Gregory R.C., Miao H.,Wang S., A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. Cancer Med. 13(5)2024. PMID38501219. PMC10949085.
17. Kanefsky J., Basse M., Sokei J., di Martino O., Valin L., Jaspers Y., Martinez E., Huhn J., Di Marcantonio D., Magee J.A., Goldman A.R., Tang H.Y., Ferraro F., Kemp S., Wiest D.L., Sykes S.M., Disruption of polyunsaturated fatty acid biosynthesis drives sting-dependent acute myeloid leukemia cell maturation and death. J Biol Chem: 107214, 2024. PMID38522521.
18. Klochkova A., Karami A.L., Fuller A.D., Parham L.R., Panchani S.R., Natarajan S., Jackson J.L., Mu A., Tan Y., Cai K.Q., Klein-Szanto A.J., Muir A.B., Tétreault M.P., Graña X., Hamilton K.E., Whelan K.A., Autophagy contributes to homeostasis in esophageal epithelium where high autophagic vesicle level marks basal cells with limited proliferation and enhanced self-renewal potential. Cell Mol Gastroenterol Hepatol, 2024. PMID38452871.
19. Mell L.K., Pugh S.L., Jones C.U., Nelson T.J., Zakeri K., Rose B.S., Zeitzer K.L., Gore E.M., Bahary J.P., Souhami L., Michalski J.M., Hartford A.C., Mishra M.V., Roach M., 3rd, Parliament M.B., Choi K.N., Pisansky T.M., Husain S.M., Malone S.C., Horwitz E.M., Feng F. Effects of androgen deprivation therapy on prostate cancer outcomes according to competing event risk: Secondary analysis of a phase 3 randomised trial. Eur Urol. 85(4): 373-381, 2024. PMID36710205.PMC10372191.
20. Muquith M., Espinoza M., Elliott A., Xiu J., Seeber A., El-Deiry W., Antonarakis E.S., Graff S.L., Hall M.J., Borghaei H., Hoon D.S.B., Liu S.V., Ma P.C., McKay R.R., Wise-Draper T., Marshall J., Sledge G.W., Spetzler D., Zhu H., Hsiehchen D., Tissue-specific thresholds of mutation burden associated with anti-pd-1/l1 therapy benefit and prognosis in microsatellite-stable cancers. Nat Cancer, 2024. PMID38528112.
21. Murayama T., Nakayama J., Jiang X., Miyata K., Morris A.D., Cai K.Q., Prasad R.M., Ma X., Efimov A., Belani N., Gerstein E.R., Tan Y., Zhou Y., Kim W., Maruyama R., Campbell K.S., Chen L., Yang Y., Balachandran S., Cañadas I., Targeting dhx9 triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer. Cancer Discov. 14(3): 468-491, 2024. PMID38189443. PMC10905673.
22. Naia Fioretto M., Colombelli K.T., da Silva C.L.F., Dos Santos S.A.A., Camargo A.C.L., Constantino F.B., Portela L.M.F., Aquino A.M., Barata L.A., Mattos R., Scarano W.R., Zambrano E., Justulin L.A., Maternal malnutrition associated with postnatal sugar consumption increases inflammatory response and prostate disorders in rat offspring. Mol Cell Endocrinol: 112223, 2024. PMID38556160.
23. Ninmer E.K., Zhu H., Chianese-Bullock K.A., von Mehren M., Haas N.B., Ross M.I., Dengel L.T., Slingluff C.L., Jr. Multipeptide vaccines for melanoma in the adjuvant setting: Long-term survival outcomes and post-hoc analysis of a randomized phase II trial. Nat Commun. 15(1): 2570, 2024. PMID38519525. PMC10959948.
24. Omil-Lima D.,Kutikov A. Reply by authors. Urology Practice. 11(1): 48-48, 2024. WOS:001163787500066.
25. Omil-Lima D., Tracy C.R., Steinberg R.L., Re: Predictors of excellent urology residents at the time of the urology match. Urology, 2024. PMID38518994.
26. Parikh M., Tangen C., Hussain M.H.A., Gupta S., Callis S., Jo Y., Harzstark A., Paller C.J., George S., Zibelman M.R., Cheng H.H., Maughan B.L., Zhang J., Pachynski R.K., Bryce A.H., Lin D.W., Quinn D.I., Lerner S.P., Thompson I.M., Dorff T.B., Lara P.N., Agarwal N., Three- and seven-month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone-sensitive prostate cancer: Results from SWOG s1216, a phase 3 randomized trial of androgen deprivation plus orteronel or bicalutamide. Eur Urol Oncol, 2024. PMID38523017.
27. Plimack E.R., Powles T., Stus V., Gafanov R., Nosov D., Waddell T., Alekseev B., Pouliot F., Melichar B., Soulières D., Borchiellini D., McDermott R.S., Vynnychenko I., Chang Y.H., Tamada S., Atkins M.B., Molife L.R., Li C.X., Perini R., Bedke J., Rini B.I. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 keynote-426 study” eur urol 84(5) (2023) 449-454. European Urology. 85(2): e58-e59, 2024. PMIDWOS:001167642100001.
28. Pratt-Chapman M.L., Tredway K., Wheldon C.W., Streed C.G., Jr., Scout N.F.N., Ose J.,Jackson S.S., Strategies for advancing sexual orientation and gender identity data collection in cancer research. JCO Oncol Pract: Op2300629, 2024. PMID38547426.
29. Reinhardt M.E., Mutyala S., Gerald M., Zhao H., Nova V., Araya Cambronero S., Patel S., Baltodano P.A., The critical blood-sparing effect of tranexamic acid (txa) in liposuction: A systematic review and meta-analysis. JPRAS Open. 40: 48-58, 2024. PMID38425698. PMC10904189.
30. Richardson D.L., Moore K.N., Vergote I., Gilbert L., Martin L.P., Mantia-Smaldone G.M., Castro C.M., Provencher D., Matulonis U.A., Stec J., Wang Y., Method M., O’Malley D.M., Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (frα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 185: 186-193, 2024. PMID38447347.
31. Rini B.I., Plimack E.R., Stus V., Gafanov R., Waddell T., Nosov D., Pouliot F., Alekseev B., Soulieres D., Melichar B., Vynnychenko I.O., Azevedo S.J., Borchiellini D., McDermott R.S., Bedke J., Tamada S., Wu S., Burgents J., Molife L.R.,Powles T., Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of keynote-426. Journal of Clinical Oncology. 41(17_SUPPL): LBA4501-LBA4501, 2023. PMIDWOS:001182783300026.
32. Ryu Tiger Y.K., Jain S., Barta S.K., Tolu S., Estrella B., Sawas A., Lue J.K., Francescone M.M., Pro B.,Amengual J.E., Phase ii study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature t-cell lymphoma. Leuk Lymphoma: 1-10, 2024. PMID38517235.
33. Schuetze S.M., Ballman K.V., Heise R., Ganjoo K.N., Davis E.J., George S., Burgess M.A., Choy E., Shepard D.R., Tinoco G., Hirbe A., Kelly C.M., Attia S., Deshpande H.A., Schwartz G.K., Siontis B.L., Riedel R.F., von Mehren M., Kozlowski E., Chen H.X., Astbury C.,Rubin B.P., A single arm phase 2 trial of trametinib in patients with locally advanced or metastatic epithelioid hemangioendothelioma. Clin Cancer Res, 2024. PMID38446990.
34. Shulman R.M., Deng M., Handorf E.A., Meyer J.E., Lynch S.M.,Arora S., Factors associated with racial and ethnic disparities in locally advanced rectal cancer outcomes. JAMA Netw Open. 7(2): e240044, 2024. PMID38421650. PMC10905315.
35. Siegel S.D., Zhang Y., Lynch S.M., Rowland J., Curriero F.C. A novel approach for conducting a catchment area analysis of breast cancer by age and stage for a community cancer center. Cancer Epidemiol Biomarkers Prev, 2024. PMID38451180.
36. Sterling J., Simhan J., Flynn B.J., Rusilko P., França W.A., Ramirez E.A., Angulo J.C., Martins F.E., Patel H.V., Higgins M., Swerdloff D., Nikolavsky D., Multi-institutional outcomes of dorsal onlay buccal mucosal graft urethroplasty in patients with postprostatectomy, postradiation anastomotic stenosis. J Urol. 211(4): 596-604, 2024. PMID38275201.
37. Stevenson J., Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J.R., Bharat A., Bruno D.S., Chang J.Y., Chirieac L.R., DeCamp M., Desai A., Dilling T.J., Dowell J., Durm G.A., Garassino M.C., Gettinger S., Grotz T.E., Gubens M.A., Lackner R.P., Lanuti M., Lin J., Loo B.W., Jr., Lovly C.M., Maldonado F., Massarelli E., Morgensztern D., Mullikin T.C., Ng T., Otterson G.A., Owen D., Patel S.P., Patil T., Polanco P.M., Riely G.J., Riess J., Shapiro T.A., Singh A.P., Tam A., Tanvetyanon T., Yanagawa J., Yang S.C., Yau E., Gregory K., Hang L. Mesothelioma: Pleural, version 1.2024. J Natl Compr Canc Netw. 22(2): 72-81, 2024. PMID38503043.
38. Sun L., Handorf E.A., Zhou Y., Borghaei H., Aggarwal C., Bauman J. Outcomes in patients treated with frontline immune checkpoint inhibition (ici) for advanced nsclc with kras mutations and stk11/keap1 comutations across pd-l1 levels. Lung Cancer. 190: 107510, 2024. PMID38432028.
39. Thompson C.L., Buchanan A.H., Myers R., Weinberg D.S., Integrating primary care, shared decision making, and community engagement to facilitate equitable access to multi-cancer early detection clinical trials. Front Oncol. 13: 1307459, 2023. PMID38486933. PMC10937460.
40. Topchu I., Bychkov I., Roshchina E., Makhov P., Boumber Y. Pip4k2b protein regulation by nsd1 in hpv-negative head and neck squamous cell carcinoma. Cancers (Basel). 16(6)2024. PMID38539515. PMC10968846.
41. Tseng M., Walton E., Egleston B.L., Fang C.Y., Pandemic effects on social capital in residents and non-residents of Chinese immigrant enclaves in Philadelphia. Wellbeing Space and Society. 62024. WOS:001175379900001.
42. Weinberg D.S., Barkun A., Liquid biopsy for colorectal cancer screening: Not so bloody fast. Gastroenterology, 2024. PMID38555972.
43. Whitehead R.A., Patel E.A., Liu J.C., Bhayani M.K. Racial disparities in head and neck cancer: It’s not just about access. Otolaryngol Head Neck Surg. 170(4): 1032-1044, 2024. PMID38258967.
44. Xirou V., Moutafi M., Bai Y., Nwe Aung T., Burela S., Liu M., Kimple R.J., Shabbir Ahmed F., Schultz B., Flieder D., Connolly D.C., Psyrri A., Burtness B., Rimm D.L. An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers. Oral Oncol. 152: 106750, 2024. PMID38547779.
45. Yang J.Y., Liu C., Deng W.Y., Wu D., Weng C.H., Zhou Y.Y., Wang K., Enhancing phenotype recognition in clinical notes using large language models: Phenobcbert and phenogpt. Patterns. 5(1)2024. WOS:001165274200001.
talbotresearchlibrary.wordpress.com 